A Phase I, Dose-Escalation, Safety and Tolerability Study of COH29 in Patients With Solid Tumors Refractory to Standard Therapy or for Which No Standard Therapy Exists
Phase of Trial: Phase I
Latest Information Update: 26 Feb 2018
At a glance
- Drugs COH 29 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- 15 Feb 2018 Planned number of patients changed from 27 to 19.
- 31 Jan 2018 Planned End Date changed from 1 Jun 2018 to 1 Nov 2018.
- 31 Jan 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Nov 2018.